Effect of trimetazidine on autonomic nervous function in patients undergoing percutaneous coronary intervention

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800017008

Enrollment

Unknown

Registered

2018-07-07

Start date

2019-01-01

Completion date

Unknown

Last updated

2018-07-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Heart Disease

Interventions

Trimetazidine group:Routine protocol + Trimetazidine

Control group:Routine protocol, include Low-molecular heparin, aspirin, clopidogrel, statin, ACEI or ARB, purge - receptor blockers and nitrates, depends on status of the disease

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: coronary heart disease patients with angina pectoris undergoing percutaneous coronary intervention.

Exclusion criteria

Exclusion criteria: 1. Patients with non-sinus rhythm, including atrial fibrillation, atrial flutter, severe atrioventricular block, sick sinus syndrome, artificial permanent cardiac pacemaker implantation, cardiac insufficiency, emergency PCI; 2. Endocrine diseases such as hyperthyroidism, hypothyroidism, etc; 3. Patients with severe liver and kidney insufficiency and viral myocarditis; 4. Patients with incomplete data.

Design outcomes

Primary

Measure	Time frame
Heart rate variability;Serum catecholamine concentration;	—

Secondary

Measure	Time frame
Cardiac color Doppler ultrasound.;	—

Countries

China

Contacts

Public ContactXiuchun Yang

yangxiuchun99013@163.com+86 15803211690

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026